SCHEMBL3201403

SCHEMBL3201403

CN(CCCNC(=O)Cn1ncc2cc3ccccc3nc21)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 7/20 0.48
MAPT P10636 7/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
POLB P06746 1/20 0.45
BCHE P06276 3/20 0.45
ACHE P22303 3/20 0.45
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
TSHR P16473 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KMT2A Q03164 4/20 0.40
HPGD P15428 1/20 0.40
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
BACE1 P56817 1/20 0.39
ATM Q13315 1/20 0.39
TRPV1 Q8NER1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14365943 0.87 TP53 (0.48) TP53MAPTSMN1; SMN2POLBBCHE
SCHEMBL3201413 0.83 BACE1 (0.45) MAPTSMN1; SMN2POLBTSHRL3MBTL1
SCHEMBL3602593 0.80 TSHR (0.57) TP53MAPTSMN1; SMN2POLBBCHE
SCHEMBL3597424 0.73 TSHR (0.41) TP53MAPTSMN1; SMN2BCHEACHE
SCHEMBL3603709 0.73 KMO (0.43) TP53MAPTSMN1; SMN2BCHEACHE
SCHEMBL3193832 0.72 MAPT (0.45) TP53MAPTPOLBBCHEACHE
SCHEMBL3600246 0.72 GAA (0.55) SMN1; SMN2POLBBCHEACHECYP3A4
SCHEMBL3596281 0.72 ACHE (0.47) TP53MAPTSMN1; SMN2POLBBCHE
SCHEMBL3178173 0.71 POLB (0.49) TP53MAPTPOLBTSHRKMT2A
SCHEMBL3586854 0.71 KDM4E (0.42) SMN1; SMN2POLBCYP3A4CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671069-B2 Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 CHEMOCENTRYX, INC. (US) 2010-03-02 US disclosed
US-7671069-B2 Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 CHEMOCENTRYX, INC. (US) 2010-03-02 US disclosed
US-7671069-B2 Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 CHEMOCENTRYX, INC. (US) 2010-03-02 US disclosed
US-20070254915-A1 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-11-01 US disclosed
WO-2007115232-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115232-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254915-A1 CXCR4 MODULATORS CXCL12, CXCR4, CXCR1 TP53 1777/4885MAPT 2809/4885SMN1; SMN2 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.